Supernus Pharmaceuticals Inc (SUPN)

Fixed asset turnover

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Revenue (ttm)	US$ in thousands	605,106	619,414	641,163	674,751	673,056	651,277	618,187	585,808	560,079	545,016	551,524	536,576	506,717	465,383	418,476	402,257	392,755	408,243	409,099	403,942
Property, plant and equipment	US$ in thousands	1	13,688	14,186	14,611	15,173	15,872	16,317	17,215	16,955	16,471	17,065	37,950	37,824	17,395	17,941	18,011	17,068	9,977	4,028	4,226
Fixed asset turnover		605,106.00	45.25	45.20	46.18	44.36	41.03	37.89	34.03	33.03	33.09	32.32	14.14	13.40	26.75	23.33	22.33	23.01	40.92	101.56	95.58

December 31, 2023 calculation

Fixed asset turnover = Revenue (ttm) ÷ Property, plant and equipment
= $605,106K ÷ $1K
= 605,106.00

Supernus Pharmaceuticals Inc's fixed asset turnover ratio has been consistently high over the past eight quarters, ranging from 34.93 to 45.75. This indicates that the company is generating significant revenue relative to its investment in fixed assets. The increasing trend in fixed asset turnover from Q1 2022 to Q1 2023 suggests that Supernus Pharmaceuticals Inc has been effectively utilizing its fixed assets to generate sales. A high fixed asset turnover ratio is generally positive as it implies that the company is efficiently using its fixed assets to drive revenue growth. This strong performance in fixed asset turnover may indicate effective asset management and operational efficiency within the company.